1.
Product Overview
2.
Research Methodology
3.
Impact of COVID-19 on Global Pharmacovigilance Market
4. Executive Summary
5. Voice of Customer
6.
Global Pharmacovigilance Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Clinical Trial Phase
(Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4)
6.2.2. By Method
(Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring, EHR Mining)
6.2.3. By Service Provider (In-House, Contract Outsourcing)
6.2.4. By End-User (Hospitals, Research Organizations, Industries)
6.2.5. By Company (2019)
6.2.6. By Region
6.3. Market Attractiveness Index
7.
Asia-Pacific Pharmacovigilance Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Clinical Trial
Phase
7.2.2. By Method
7.2.3. By Service Provider
7.2.4. By End-User
7.2.5. By Country
7.3.
Market Attractiveness Index
7.4.
Asia-Pacific: Country Analysis
7.4.1. China Pharmacovigilance
Market Outlook
7.4.1.1.
Market Size & Forecast
7.4.1.1.1.
By Value
7.4.1.2.
Market Share & Forecast
7.4.1.2.1.
By Clinical Trial Phase
7.4.1.2.2.
By Method
7.4.1.2.3.
By Service Provider
7.4.1.2.4.
By End-User
7.4.2. India Pharmacovigilance
Market Outlook
7.4.2.1.
Market Size & Forecast
7.4.2.1.1.
By Value
7.4.2.2.
Market Share & Forecast
7.4.2.2.1.
By Clinical Trial Phase
7.4.2.2.2.
By Method
7.4.2.2.3.
By Service Provider
7.4.2.2.4.
By End-User
7.4.3. Japan Pharmacovigilance
Market Outlook
7.4.3.1.
Market Size & Forecast
7.4.3.1.1.
By Value
7.4.3.2.
Market Share & Forecast
7.4.3.2.1.
By Clinical Trial Phase
7.4.3.2.2.
By Method
7.4.3.2.3.
By Service Provider
7.4.3.2.4.
By End-User
7.4.4. South Korea Pharmacovigilance
Market Outlook
7.4.4.1.
Market Size & Forecast
7.4.4.1.1.
By Value
7.4.4.2.
Market Share & Forecast
7.4.4.2.1.
By Clinical Trial Phase
7.4.4.2.2.
By Method
7.4.4.2.3.
By Service Provider
7.4.4.2.4.
By End-User
7.4.5. Singapore
Pharmacovigilance Market Outlook
7.4.5.1.
Market Size & Forecast
7.4.5.1.1.
By Value
7.4.5.2.
Market Share & Forecast
7.4.5.2.1.
By Clinical Trial Phase
7.4.5.2.2.
By Method
7.4.5.2.3.
By Service Provider
7.4.5.2.4.
By End-User
7.4.6. Australia
Pharmacovigilance Market Outlook
7.4.6.1.
Market Size & Forecast
7.4.6.1.1.
By Value
7.4.6.2.
Market Share & Forecast
7.4.6.2.1.
By Clinical Trial Phase
7.4.6.2.2.
By Method
7.4.6.2.3.
By Service Provider
7.4.6.2.4.
By End-User
8.
Europe Pharmacovigilance Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Clinical Trial
Phase
8.2.2. By Method
8.2.3. By Service Provider
8.2.4. By End-User
8.2.5. By Country
8.3.
Market Attractiveness Index
8.4.
Europe: Country Analysis
8.4.1. France
Pharmacovigilance Market Outlook
8.4.1.1.
Market Size & Forecast
8.4.1.1.1.
By Value
8.4.1.2.
Market Share & Forecast
8.4.1.2.1.
By Clinical Trial Phase
8.4.1.2.2.
By Method
8.4.1.2.3.
By Service Provider
8.4.1.2.4.
By End-User
8.4.2. Germany
Pharmacovigilance Market Outlook
8.4.2.1.
Market Size & Forecast
8.4.2.1.1.
By Value
8.4.2.2.
Market Share & Forecast
8.4.2.2.1.
By Clinical Trial Phase
8.4.2.2.2.
By Method
8.4.2.2.3.
By Service Provider
8.4.2.2.4.
By End-User
8.4.3. United Kingdom
Pharmacovigilance Market Outlook
8.4.3.1.
Market Size & Forecast
8.4.3.1.1.
By Value
8.4.3.2.
Market Share & Forecast
8.4.3.2.1.
By Clinical Trial Phase
8.4.3.2.2.
By Method
8.4.3.2.3.
By Service Provider
8.4.3.2.4.
By End-User
8.4.4. Italy Pharmacovigilance
Market Outlook
8.4.4.1.
Market Size & Forecast
8.4.4.1.1.
By Value
8.4.4.2.
Market Share & Forecast
8.4.4.2.1.
By Clinical Trial Phase
8.4.4.2.2.
By Method
8.4.4.2.3.
By Service Provider
8.4.4.2.4.
By End-User
8.4.5. Russia Pharmacovigilance
Market Outlook
8.4.5.1.
Market Size & Forecast
8.4.5.1.1.
By Value
8.4.5.2.
Market Share & Forecast
8.4.5.2.1.
By Clinical Trial Phase
8.4.5.2.2.
By Method
8.4.5.2.3.
By Service Provider
8.4.5.2.4.
By End-User
8.4.6. Spain Pharmacovigilance
Market Outlook
8.4.6.1.
Market Size & Forecast
8.4.6.1.1.
By Value
8.4.6.2.
Market Share & Forecast
8.4.6.2.1.
By Clinical Trial Phase
8.4.6.2.2.
By Method
8.4.6.2.3.
By Service Provider
8.4.6.2.4.
By End-User
9.
North America Pharmacovigilance Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Clinical Trial
Phase
9.2.2. By Method
9.2.3. By Service Provider
9.2.4. By End-User
9.2.5. By Country
9.3.
Market Attractiveness Index
9.4.
North America: Country Analysis
9.4.1. United States Pharmacovigilance
Market Outlook
9.4.1.1.
Market Size & Forecast
9.4.1.1.1.
By Value
9.4.1.2.
Market Share & Forecast
9.4.1.2.1.
By Clinical Trial Phase
9.4.1.2.2.
By Method
9.4.1.2.3.
By Service Provider
9.4.1.2.4.
By End-User
9.4.2. Mexico Pharmacovigilance
Market Outlook
9.4.2.1.
Market Size & Forecast
9.4.2.1.1.
By Value
9.4.2.2.
Market Share & Forecast
9.4.2.2.1.
By Clinical Trial Phase
9.4.2.2.2.
By Method
9.4.2.2.3.
By Service Provider
9.4.2.2.4.
By End-User
9.4.3. Canada Pharmacovigilance
Market Outlook
9.4.3.1.
Market Size & Forecast
9.4.3.1.1.
By Value
9.4.3.2.
Market Share & Forecast
9.4.3.2.1.
By Clinical Trial Phase
9.4.3.2.2.
By Method
9.4.3.2.3.
By Service Provider
9.4.3.2.4.
By End-User
10.
South America Pharmacovigilance Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Clinical Trial
Phase
10.2.2. By Method
10.2.3. By Service Provider
10.2.4. By End-User
10.2.5. By Country
10.3.
Market Attractiveness Index
10.4.
South America: Country Analysis
10.4.1. Brazil Pharmacovigilance
Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1.
By Value
10.4.1.2. Market Share & Forecast
10.4.1.2.1.
By Clinical Trial Phase
10.4.1.2.2.
By Method
10.4.1.2.3.
By Service Provider
10.4.1.2.4.
By End-User
10.4.2. Argentina Pharmacovigilance
Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1.
By Value
10.4.2.2. Market Share & Forecast
10.4.2.2.1.
By Clinical Trial Phase
10.4.2.2.2.
By Method
10.4.2.2.3.
By Service Provider
10.4.2.2.4.
By End-User
10.4.3. Colombia
Pharmacovigilance Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1.
By Value
10.4.3.2. Market Share & Forecast
10.4.3.2.1.
By Clinical Trial Phase
10.4.3.2.2.
By Method
10.4.3.2.3.
By Service Provider
10.4.3.2.4.
By End-User
11.
Middle East and Africa Pharmacovigilance Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Clinical Trial
Phase
11.2.2. By Method
11.2.3. By Service Provider
11.2.4. By End-User
11.2.5. By Country
11.3.
Market Attractiveness Index
11.4.
MEA: Country Analysis
11.4.1. South Africa
Pharmacovigilance Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1.
By Value
11.4.1.2. Market Share & Forecast
11.4.1.2.1.
By Clinical Trial Phase
11.4.1.2.2.
By Method
11.4.1.2.3.
By Service Provider
11.4.1.2.4.
By End-User
11.4.2. Saudi Arabia Pharmacovigilance
Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1.
By Value
11.4.2.2. Market Share & Forecast
11.4.2.2.1.
By Clinical Trial Phase
11.4.2.2.2.
By Method
11.4.2.2.3.
By Service Provider
11.4.2.2.4.
By End-User
11.4.3. UAE Pharmacovigilance
Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1.
By Value
11.4.3.2. Market Share & Forecast
11.4.3.2.1.
By Clinical Trial Phase
11.4.3.2.2.
By Method
11.4.3.2.3.
By Service Provider
11.4.3.2.4.
By End-User
12.
Market Dynamics
12.1.
Drivers
12.2.
Challenges
13.
Market Trends & Developments
14.
Competitive Landscape
14.1.
Competition Outlook
14.2.
Players Profiled (Leading Companies)
14.2.1.
F. Hoffmann-La Roche
14.2.2.
Accenture
14.2.3.
Cognizant
14.2.4.
Laboratory Corporation of America Holdings
14.2.5.
IBM Corporation
14.2.6.
ArisGlobal
14.2.7.
Foresight Group International AG
14.2.8.
ICON PLC
14.2.9.
Capgemini
14.2.10.
United BioSource Corporation
14.2.11.
Wipro Ltd
14.2.12.
BioClinica
14.2.13.
Bristol-Myers Squibb
14.2.14.
Clinquest Group
14.2.15.
Novartis International
14.2.16.
GlaxoSmithKlin
14.2.17.
PAREXEL International
14.2.18.
iGATE Corporation
14.2.19.
iMEDGlobal Corporation
14.2.20.
inVentiv Health
15. Strategic Recommendations
16. About Us & Disclaimer